PRAGMATIC SEMICONDUCTOR LIMITED

Financial Health Score: B+

Explanation: Pragmatic Semiconductor Limited presents as a structurally robust and well-supported deep-tech scaleup, earning a B+ grade. The company exhibits a strong "immune system" through a heavyweight board of directors and significant backing from a major venture capital firm. However, the absence of detailed quantitative financial metrics (such as cash flow, retained earnings, or debt levels) in the current chart prevents a perfect score. As is typical for companies in the capital-intensive semiconductor manufacturing sector, the "patient" is likely consuming significant cash to fuel growth, making it reliant on continued capital injections rather than self-sustaining profitability.

Key Vital Signs

• Corporate Pulse (Filing & Status): Strong. The company is Active, with accounts filed up to 31 December 2025 and confirmation statements up to date. There are no overdue filings, indicating a healthy, regular heartbeat and good administrative compliance.
• Genetic Lineage (Corporate History): Adapted. The company has evolved significantly since its incorporation in 2010, pivoting from "Fusionform Limited" to "Pragmatic Printing Limited," and finally to "Pragmatic Semiconductor Limited" in November 2020. This shows a healthy ability to mutate and adapt its business model to the market.
• Blood Supply (Capital & Ownership): Transfusion Dependent. The share capital is a nominal £1.00, which is standard for venture-backed companies where the real value sits in share premiums rather than nominal capital. Cambridge Innovation Capital (CIC) holds a controlling interest (25-50% shares and voting rights). This indicates the company is receiving vital capital transfusions from institutional investors rather than generating its own lifeblood through retained earnings.
• Immune System (Board & Officers): Exceptionally Robust. The board features a high concentration of heavy-hitting industry veterans, including former and current executives from ARM (CTO, VP of Segment Strategy), mergers & acquisitions specialists, and corporate finance leaders. This provides an excellent defence against strategic missteps.
• Metabolic Rate (Industry): High Burn. Operating under SIC code 26110 (Manufacture of electronic components), this business requires heavy capital expenditure (CapEx) for fabrication facilities. A high metabolic rate (cash burn) is expected as the company scales its manufacturing capabilities.

Diagnosis

Condition: Late-Stage Scaleup with Institutional Backing

Pragmatic Semiconductor is not a fledgling startup; it is a 14-year-old entity that has successfully navigated a strategic pivot into the deep-tech semiconductor space. The financial data reveals a business that is structurally sound but fundamentally reliant on external life support (venture capital).

The presence of Cambridge Innovation Capital as a major shareholder, combined with a board stacked with ARM alumni and corporate financiers, suggests the company is in a high-growth phase, likely preparing for a major liquidity event (such as an IPO or acquisition) or scaling up manufacturing capacity. The nominal £1 share capital confirms that the equity structure is driven by successive rounds of venture funding rather than accumulated profits.

Symptoms of Note: While there are no visible symptoms of immediate distress (such as overdue filings or liquidation risk), the inherent danger for a company in this "scaleup" phase is cash flow anaemia. Without seeing the specific P&L reserves or net current assets, one must assume the business is consuming cash rapidly to fund its "revolutionising semiconductor fabrication" mandate.

Recommendations

To improve its financial wellness and transition from a B+ to an A-grade investment, the patient should focus on the following preventative care and treatments:

1. Monitor the Cash Runway (Oxygen Supply): In capital-intensive manufacturing, running out of cash is the primary cause of sudden corporate death. Management must ensure that the current funding runway extends far enough to hit the next major operational milestone (e.g., full-scale production) before requiring another capital transfusion.
2. Leverage the Board's Strategic Immunity: With such a high-calibre board, the company must ensure it is actively using these directors for strategic partnerships and supply chain negotiations, rather than just as figureheads. The ARM connections, in particular, should be leveraged to secure long-term customer contracts.
3. Plan for Capital Efficiency: As the company scales its manufacturing, it should focus on converting its capital expenditure into revenue-generating assets as quickly as possible to reduce the cash burn rate and demonstrate a path to self-sustaining "healthy cash flow."
4. Maintain Rigorous Corporate Hygiene: The transition from a VC-backed scaleup to a publicly listed or acquired entity requires immaculate financial records. Continuing to file accounts and confirmation statements on time is essential to maintaining investor confidence.